Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment.

We isolated a SARS-CoV-2 BA.2 variant from a person with COVID-19 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing were performed with both parental SARS-CoV-2 and multiple variants of concern. We found that neither NM resistance nor absence of neutralizing immunity were likely causes of the recrudescence.
Date: 20 Jun 2022
DOI: 10.1093/cid/ciac496
Journal: Clinical Infectious Diseases
Pubmed ID: 35723411
ML/Curated Information
Viruses: SARS-CoV-2
Article Type(s): Research
Topics: Clinical Reports, Therapeutics